Philogen completed the merger with Palio Ordinarie in a $596m deal.

Philogen, a biotech company that develops biotech products for the imaging and therapy of life, completed the merger with Palio Ordinarie in a $596m deal. This merger made it possible to dissolve the vehicle Palio Ordinarie, contributing towards the generation of a free float equal to 17% for the listing process.